Series A
$106M
AN Venture Partners · LeadThe Column Group · LeadCure Ventures · Lead
Open roles0
Total raised$106M
Team size1-10
Founded · StageSeries A
We pull jobs from sources most job seekers never check
About the company
What they build and who they serve.
Tortugas Neuroscience is a clinical-stage biotechnology company based in Framingham, Massachusetts. It focuses on developing potential treatments for major neurology and neuropsychiatric disorders, including schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies. The company's pipeline includes assets licensed from Eisai and Hansoh Pharmaceutical, with a focus on small molecules with de-risked mechanisms of action.
Why it matters
Signals from funding, traction, and product direction.
- Tortugas Neuroscience launched with $106 million in combined Seed and Series A financing.
- The financing was led by Cure Ventures and The Column Group, with participation from AN Venture Partners.
- The company is developing a clinical-stage pipeline licensed from Eisai and Hansoh Pharmaceutical targeting schizophrenia, tinnitus, and focal epilepsy.
- Led by CEO Jeff Jonas and CSO Al Robichaud, both former executives at Sage Therapeutics.
Funding history
Rounds and investors over time, newest first.
In the news
Press, announcements, and coverage about this company.
Investors
AN Venture PartnersThe Column GroupCure Ventures
Focus areas
BiotechnologyClinical TrialsHealthtechMental HealthNeuroscience
No open roles on the board yet
We do not have indexed listings for Tortugas Neuroscience right now. Roles may still be open on the company site—we will add them here when they appear in our feed.
Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job posts